OKYO Pharma Ltd
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
OKYO | US
Overview
Corporate Details
- ISIN(s):
- US6793451088
- LEI:
- Country:
- United States of America
- Address:
- 55 PARK LANE, LONDON
- Website:
- https://okyopharma.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for inflammatory eye diseases and ocular pain. The company focuses on addressing significant unmet medical needs, primarily in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod, is a novel chemerin receptor agonist designed to produce anti-inflammatory effects and reduce neuropathic pain. OKYO is the first company to receive Investigational New Drug (IND) clearance from the U.S. FDA to begin clinical trials for a drug specifically targeting NCP, a condition for which there are no approved treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all OKYO Pharma Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OKYO Pharma Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OKYO Pharma Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
